1Revenue of $590.1K was generated entirely by newly acquired subsidiaries, marking the company's pivot from skincare to a diversified holding model.
2Net loss deepened to -$7.7M, a 24.0% year-over-year decline, as operating expenses increased due to corporate restructuring, acquisition due diligence, and financing efforts.
3Gross margin was 31.4%, with cost of revenue increasing in line with sales, and management noting that inflation could adversely affect future margin levels.
4Operating cash flow was -$5.9M, with free cash flow at -$6.4M, reflecting heavy cash burn as capital expenditures surged to $442K from $9K in the prior year.
5The strategic shift was completed with the divestiture of the skincare business and acquisitions establishing four operating subsidiaries, though this diversification increases management complexity.
6Northstrive Biosciences' lead asset EL-22 remains preclinical, with research and development costs driven by ongoing work on the project and pre-IND meeting expenses.
7Liquidity is dependent on external financing, with principal requirements for working capital, capital expenditure, and R&D; the company expects improvement from potential sales of investment securities.